AbbVie raises 2026 profit forecast and quarterly dividend 5.2%

AbbVie (ABBV) raised its 2026 adjusted earnings forecast and its quarterly dividend alongside third-quarter results released on Oct. 30.

Shares rose 1.7% to $295.61 in regular trading as of 9:42 a.m. ET, from a regular-session close of $290.79.

Adjusted diluted earnings per share were $3.82, in line with the $3.83 consensus estimate compiled by Finnhub. Net revenues of $17.40 billion were below the $17.66 billion consensus estimate compiled by Finnhub.

Here's how the company did:

• Adjusted EPS: $3.82 vs. $1.86 a year earlier, against a $3.83 consensus estimate compiled by Finnhub
• GAAP diluted EPS: $2.37 vs. $0.10 a year earlier
• Revenue: $17.40 billion vs. $15.78 billion a year earlier, against a $17.66 billion consensus estimate compiled by Finnhub

Net revenues rose 10.3% on a reported basis, or 10.5% on an operational basis, which uses prior-year exchange rates.

"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio," said Robert A. Michael, chairman and chief executive officer.

Segment results

Immunology revenue reached $9.165 billion, up 16.3% on a reported basis.

Skyrizi sales were $5.776 billion, up 22.7%, and Rinvoq sales were $2.706 billion, up 23.9%.

Humira fell to $683 million, down 31.2%.

Neuroscience net revenues were $3.389 billion, up 19.4%, led by Vraylar at $1.068 billion and Botox Therapeutic at $1.080 billion.

Oncology revenues were $1.696 billion, up 0.8%, and aesthetics revenues were $1.176 billion, down 1.4%.

Costs and charges

On a GAAP basis, the gross margin ratio was 75.4%.

Acquired IPR&D and milestones expense was 1.2% of net revenues and reduced both GAAP and adjusted diluted EPS by $0.11 per share.

Acquisition and integration costs were $408 million pre-tax, primarily related to the Apogee Therapeutics acquisition.

The company said it completed the Apogee Therapeutics acquisition, which includes zumilokibart, a late-stage IL-13 antibody for atopic dermatitis.

Changes in the fair value of contingent consideration were $829 million pre-tax.

2026 guidance

AbbVie raised its 2026 adjusted diluted EPS guidance to $13.95 to $13.99, from $13.76 to $13.96.

The range includes $0.69 per share of acquired IPR&D and milestones expense incurred through the third quarter, and excludes expense that may be incurred later in 2026.

"Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend," Michael said.

Dividend increase

The board declared a quarterly cash dividend of $1.82 per share, up from $1.73, an increase of 5.2%.

The dividend is payable Feb. 16, 2027, to shareholders of record as of Jan. 15, 2027.

Since its 2013 inception, AbbVie has increased its quarterly dividend by 355%, the company said. AbbVie is a member of the S&P Dividend Aristocrats Index.